Financial Daily from THE HINDU group of publications
Friday, Dec 02, 2005


Group Sites

Corporate - Announcements

USFDA nod for Lupin drug

Our Bureau

MUMBAI: Lupin Ltd has announced that it has received US Food and Drug Administration (USFDA) approval for its Abbreviated New Drug Application (ANDA) for Cephalexin capsules USP 250 mg and 500 mg.

The US market for Cephalexin capsules is estimated at $80 million.

This is the company's eighth ANDA approval by the USFDA so far and the third in this financial year.

Earlier this year, the company had received approvals from the USFDA for Lisinopril tablets and Cephalexin for oral suspension.

"The approval makes the company one of the select few integrated players who offer both Cephalexin capsules and suspension in the US market," Lupin said in a notice to the BSE.

A main stay cephalosporin antibiotic, Cephalexin is indicated for the treatment of respiratory tract infections.

Article E-Mail :: Comment :: Syndication :: Printer Friendly Page

More Stories on : Announcements

Stories in this Section
ONGC may contest I-T Dept's additional claim of Rs 1,000 cr

Perlecan begins phase-I trials on obesity drug
Ranbaxy to launch 2 AIDS drugs
Colgate 30 pc second interim
USFDA nod for Lupin drug
Piramal group makes open offer for 20 pc stake in Dawn Mills
IVRCL raises $65 m through FCCBs
Terex Pegson to source components worth $2 million
Why MNCs need to create products for India, in India
HLL tea unit demerger okayed
ONGC appoints consultants for due diligence of SPIC Petro
Suryavanshi Spinning plans merger
Sical to raise funds for iron ore terminal
Nalco signs pact with NMDC
Bajaj Auto expects to grow at 17-20 pc after April
Brooke Bond initiative on education in Mangalore
Trayons promoters sign OTS pact with IDBI Bank
Siemens bets on India for Asian growth
Escorts Construction expects 40 pc turnover growth
IOC likely to be hit by pricing pressures
Maruti sales up 11% in Nov
Hero Honda Nov sales up 6.5 pc
Bajaj Auto Nov sales flat
TVS Motor sales up 5 pc

The Hindu Group: Home | About Us | Copyright | Archives | Contacts | Subscription
Group Sites: The Hindu | Business Line | The Sportstar | Frontline | The Hindu eBooks | The Hindu Images | Home |

Copyright 2005, The Hindu Business Line. Republication or redissemination of the contents of this screen are expressly prohibited without the written consent of The Hindu Business Line